Molecular Action of Lenalidomide in Lymphocytes and Hematologic Malignancies

The immunomodulatory agent, lenalidomide, is a structural analogue of thalidomide approved by the US Food and Drug Administration for the treatment of myelodysplastic syndrome (MDS) and multiple myeloma (MM). This agent is also currently under active investigation for the treatment of chronic lympho...

Descripción completa

Detalles Bibliográficos
Autores principales: McDaniel, Jessica M., Pinilla-Ibarz, Javier, Epling-Burnette, P. K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3409527/
https://www.ncbi.nlm.nih.gov/pubmed/22888354
http://dx.doi.org/10.1155/2012/513702

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3409527/
https://www.ncbi.nlm.nih.gov/pubmed/22888354
http://dx.doi.org/10.1155/2012/513702

Ejemplares similares